Caris Life Sciences, Inc. (CAI) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-07

Key Insights

Caris Life Sciences announced Q1 2026 financial results on May 7, 2026, indicating the company is maintaining its regular earnings reporting cadence and SEC compliance as a Nasdaq-listed public company.
The filing is a routine 8-K for earnings announcement with the actual financial details contained in the press release (Exhibit 99.1), which is not provided in this document, limiting detailed analysis of operational performance.
The company maintains emerging growth company status, which provides regulatory flexibility for compliance timelines, though it has not elected to use extended transition periods for new accounting standards.
Senior Vice President and CFO Luke Power signed the filing, confirming continued stability in the company's financial leadership and oversight.

Want the newest filings?

This analysis covers the filing from 2026-05-07. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-02

Caris Life Sciences has secured a significant new credit facility, including a $400 million initial term loan, a $300 million delayed draw term loan, and a $500 million incremental facility. This additional financing provides the company with substantial resources to pursue strategic acquisitions and growth initiatives.
The new credit agreement replaces the company's previous credit facility, suggesting improved financing terms and conditions that may benefit the company's financial flexibility and cost of capital.
The credit agreement includes customary covenants and restrictions, which investors should monitor to ensure the company maintains compliance and financial discipline as it executes on its growth plans.

Filed: 2026-02-26

Caris Life Sciences reported its Q4 2025 and full-year 2025 financial results, providing investors with an update on the company's operations and financial performance.
The company announced progress on its Caris Detect multi-cancer early detection test, with the completion of the interim readout of the Achieve 1 study supporting the upcoming launch of the product.
Investors will likely be interested in the financial details and the company's outlook for the Caris Detect test, which could be a significant growth driver for Caris Life Sciences.

Filed: 2026-01-12

Caris Life Sciences reported preliminary unaudited Q4 2025 and full-year 2025 financial results, indicating the company's continued growth and performance.
The company will be presenting at the 2026 J.P. Morgan Healthcare Conference, providing an opportunity for investors to get updated on the company's strategic initiatives.
As an emerging growth company, Caris Life Sciences has elected to take advantage of the extended transition period for complying with new or revised financial accounting standards.

Other reports for Caris Life Sciences, Inc.

Quarterly Report Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.